Kazia Therapeutics (KZIA) Long-Term Deferred Tax (2011)

Kazia Therapeutics (KZIA) posted Long-Term Deferred Tax of $59.8 million for Q4 2011.

Kazia Therapeutics (KZIA) Long-Term Deferred Tax (2011) Analysis & Trends

Kazia Therapeutics' Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $59.8 million for Q4 2011.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $59.8 million in Q4 2011, while the trailing twelve-month figure through Dec 2011 was $59.8 million (changed N/A YoY) and the FY2011 annual result came in at $61.0 million, changed N/A from the prior year.
Long-Term Deferred Tax was $59.8 million for Q4 2011 at Kazia Therapeutics.
Across five years, Long-Term Deferred Tax topped out at $59.8 million in Q4 2011 and bottomed at $59.8 million in Q4 2011.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Kazia Therapeutics	4.11 Mn	4.11 Mn	-

Download Data

Date	Value
Dec 31, 2011	59.77 Mn